Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLM-019
- Development stage
- Unknown
- Lead developer
- Tsubota Laboratory
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
TLM-019 is a small molecule therapeutic candidate developed by Tsubota Laboratory for the treatment of dry eye disease. The drug is designed to act as a pharmacological mimetic of violet light (360–400 nm) exposure, which has been identified by Tsubota Laboratory's research as a critical regulator of ocular surface homeostasis. TLM-019 functions as an agonist of Opsin 5 (OPN5), also known as neuropsin, a non-visual photoreceptor expressed in the eye. Activation of the OPN5 pathway is believed to stimulate natural tear secretion and improve the stability of the tear film. TLM-019 is currently in Phase 2 clinical development as an ophthalmic solution.
02
Targets
OPN5 (Opsin-5 receptor)
Beyond the preview
Go deeper on TLM-019.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLM-019.